# **FUJIFILM**

# **FUJINON**

15090116 pg/083

# **510 (k) Summary**

APR 2 2 2009

# Date Prepared [21 CFR 807.92(a)(1)]

1/16/2009

# Submitter's Information [21 CFR 807.92(a)(1)]

This 510(k) is being submitted by Joseph Azary on behalf of Fujinon Inc.

#### Contact / Submitter:

Joseph Azary Orchid Design 80 Shelton Technology Center Shelton, CT 06484

Tel: (203) 922-0105 Fax: (203) 922-0130

#### Sponsor / U.S. Distributor:

Fujinon Inc.

10 High Point Drive

Wayne, NJ 07470

Contact: Gina Walljasper

Telephone: 973-633-5600

FDA Establishment Registration# 2431293

#### Manufacturer:

**Fujinon Corporation** 

1-324 Uetake-Cho

Kita-Ku, Saitama-Shi

Saitama 331-9624, Japan

Contact: Masayuji Ooyatsu FDA Establishment Registration# 9610875

K090116 Pg 293

#### Trade Name, Common Name, Classification [21 CFR 807.92(a)(2)]\

Device Trade or Proprietary Name:

Fujinon EC-450BI5

Common, Usual, or Classification Name:

Colonoscope

Classification:

Class II, 21 CFR 876.1500, FDF

# Predicate Device [21 CFR 807.92(a)(3)]

• Fuiinon EG-450HL5 (K041903)

• Fujinon EN-450P5/20 (K040048)

# Description of the Device [21 CFR 807.92(a)(4)]

The device is intended for the optical visualization of the gastrointestinal tract. This includes the rectum, large and small intestine. It is intended for observation, diagnosis, and endoscopic treatment.

The Fujinon double balloon enteroscopy system utilizes specialized balloons and over-tube to ensure complete positioning of the colonoscope. The tip of the scope can be smoothly inserted to reach the area of diagnosis. This allows for access to hard to reach areas within the bottom portion of the small intestine.

The EC-450BI5 consists of the following portions / parts:

- Control portion to provide grip for holding the endoscope and for the operation of the endoscope.
- LG Flexible Portion Contains the light guide, air/water supply tube, suction tube, and cables.
- Bending Portion
- Distal End Contains objective lens, air/water nozzles, forceps channel.

The EC-450BI5 is used with balloons (BS-1 or BS-2) and an Over-Tube (TS-13101), as well as the balloon pump. The balloon pump, balloons and over-tube were introduced and included as part of the Double Balloon Enteroscopy 510(k).

The EC-450BI5 is used with a Processor (4400) and other peripheral items such as VCR, Television Monitor, and Printers.

# Intended Use [21 CFR 807.92(a)(5)]

The device is intended for the optical visualization of the gastrointestinal tract. This includes the rectum, large and small intestine. It is intended for observation, diagnosis, and endoscopic treatment.

K090116 Pg 303

# Technological Characteristics [21 CFR 807.92(a)(6)]

Fujinon, Inc. believes that the subject device is substantially equivalent to the predicate device. The subject device has the <u>same</u> indications for use, material composition, characteristics, reprocessing/sterilization method as the predicate. The subject device uses the same processor and peripherals as the predicate device.

The main difference is the use of a colonoscope for with the double balloon enteroscopy accessories or retrograde application of the double balloon enteroscopy system.

### Performance Data [21 CFR 807.92(b)(1)]

The materials in the endoscope are identical to the materials used in the predicate device. Additionally, the device contains the same electrical configurations as the predicate devices.

#### Conclusion [21 CFR 807.92(b)(3)]

We believe the changes are minor and conclude that the subject devices are as safe and effective as the predicate device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Fujinon, Inc. % Mr. Joseph M. Azary Orchid Design 80 Shelton Technology Center Shelton CT 06484

APR 2 2 2009

Re: K090116

Trade/Device Name: Fujinon EC-450BI5 Regulation Number: 21 CFR 876.1500

Regulation Name: Endoscope and accessories

Regulatory Class: II Product Code: FDF, FED Dated: January 16, 2009 Received: January 23, 2009

Dear Mr. Azary:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxx	(Gastroenterology/Renal/Urology)	(240) 276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	(240) 276-0115
21 CFR 892.xxx	(Radiology)	(240) 276-0120
Other		(240) 276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please contact the CDRH/Office of Surveillance and Biometrics/Division of Postmarket Surveillance at 240-276-3464. For more information regarding the reporting of adverse events, please go to <a href="http://www.fda.gov/cdrh/mdr/">http://www.fda.gov/cdrh/mdr/</a>.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Janine M. Morris

Acting Director, Division of Reproductive,
Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

**Enclosure** 

Device Name: Fujinon EC-450B	315	
The device is intended for the large and small intestines. It	ne optical visualization of the ga t is intended for observation, dia	strointestinal tract. This includes the reagnosis, and endoscopic treatment.
		•
		•
	. •	
•		
·		
(PLEASE DO NOT WRITE		
Concur Prescription Use X		
Concur	rrence of CDRH Office of Devi	ce Evaluation (ODE)
Concur Prescription Use X	rrence of CDRH Office of Devi	ce Evaluation (ODE)  Over-The-Counter Use
Prescription Use X (Per 21 CFR 801.109)	OR	ce Evaluation (ODE)  Over-The-Counter Use
Prescription Use X (Per 21 CFR 801.109)	OR  OR  Abdominal,	ce Evaluation (ODE)  Over-The-Counter Use

.